Summary
12 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 75% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 75%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $137.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 0
- Sell 1
Today's price within the analysts' price targets
The average target of $54.4 is 117% above today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 91%
- Europe 8.2%
- Other 1.1%
UNITED STATES brings in 91% of revenue.
Segments in detail